Psilocybin trials show glaring blind spots, while low-dose LSD changes reward processing in depressed brains
Psychedelic research is hitting some growing pains. While hundreds of studies are underway, regulatory hurdles are mounting and researchers are discovering that the devil is in the details they're not reporting.
๐ Psilocybin trials are missing the forest for the trees
Researchers evaluated 13 psilocybin clinical trials for depression using new reporting guidelines and found some glaring blind spots:
Only 15.6% of required details about "set and setting" (the psychological and physical environment) were fully reported, despite these factors being crucial for psychedelic outcomes
While 100% of trials documented medical procedures and 92.3% described session activities, 84.6% failed to mention cultural competence measures and 92.3% didn't describe room decorations or objects
84.6% of protocols provided no information about patient access to nature during treatment
Why it matters: These contextual details aren't just nice-to-havesโthey may directly influence whether psychedelic therapy works, yet most trials aren't systematically tracking them.
Key Findings
๐ Ketamine dramatically reduces suicide thoughts in high-risk patients
A meta-analysis of 21 studies with 927 participants found ketamine's anti-suicidal effects are both rapid and substantial:
Large effect size of -1.40 for reducing suicidal thoughts, with benefits appearing strongest in younger patients and those with severe ideation
Most common side effects were dissociation (38.8%), nausea (31.6%), and dizziness (24.7%)
Effects were particularly pronounced in younger individuals and those with the most severe suicidal thoughts
๐ง Low-dose LSD changes reward processing in depressed brains
Researchers gave 39 participants either 26 ฮผg of LSD or placebo and measured brain responses during a monetary reward task:
LSD increased brain responses to financial losses (vs wins) only in participants with higher baseline depression scores
This enhanced response to losses was linked to improved mood both immediately and 48 hours after the LSD session
The effect suggests LSD may help depressed brains process emotional information about rewards more effectively
๐ Firefighters face major barriers to ketamine therapy for PTSD
Interviews with six firefighters enrolled in a ketamine-assisted therapy program revealed systemic obstacles:
PTSD rates in firefighters average 7.3% compared to 1.3-3.5% in the general population
Major themes included feeling "stuck and reaching a breaking point," stigma around both PTSD and ketamine treatment, and substantial financial and logistical barriers
Self-advocacy was crucial for navigating access to treatment, suggesting the system isn't set up to support those who need it most
๐ฌ Psychedelics boost specific brain waves linked to visual perception
Using brain imaging in awake mice, researchers found that psychedelic drugs specifically amplify 5-Hz brain oscillations:
5-Hz oscillations occurred in both visual and retrosplenial cortex areas, both spontaneously and when triggered by visual stimulation
Psychedelic 5-HT2A receptor activation significantly increased the power, occurrence, and persistence of these oscillations
This pattern may explain how psychedelics create visual hallucinations through enhanced "top-down" brain control
โ ๏ธ Recreational ketamine withdrawal hits memory and brain chemistry hard
Adolescent female rats given recreational doses of ketamine (10 mg/kg for 3 days) showed broad cognitive impairments 24 hours after stopping:
All memory types testedโepisodic, social, and working memoryโwere significantly impaired during early withdrawal
Serotonin and norepinephrine levels dropped substantially in both the hippocampus and prefrontal cortex
The study mimicked weekend party use patterns, suggesting even short-term recreational use may have lasting effects
๐ฏ Psychedelics show promise for treatment-resistant depression
A systematic review of 15 studies found consistent benefits across different psychedelic compounds for the hardest-to-treat depression cases:
10 randomized controlled trials and 5 open-label studies all showed efficacy for treatment-resistant depression
Benefits appeared across multiple classes of psychedelics, not just one specific compound
Results suggest psychedelics may work through different mechanisms than traditional antidepressants, offering hope for patients who don't respond to standard treatments
Implications
The psychedelic therapy field is experiencing growing pains as it moves from promising early results toward mainstream medicine. While compounds like ketamine are showing robust effects for severe conditions like suicide risk, the research infrastructure still needs workโfrom better reporting standards to addressing access barriers for those who need these treatments most.
Studies in this issue
Primary sources used for this newsletter.
- Using ReSPCT guidelines to improve reporting in psilocybin clinical trial plansmain storyEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology2026-01-17PMID 41546918
- Brain reward system activity after low doses of LSD in people with depressed moodkey findingJournal of psychopharmacology (Oxford, England)2026-01-13PMID 41529826
- Short-term ketamine withdrawal affects memory and mood-related brain chemicals in adolescent female ratskey findingBehavioural brain research2026-01-18PMID 41548718
- Possible Benefits of Psychedelics for Hard-to-Treat Depression: Fact or Fiction? A Reviewkey findingJournal of clinical psychopharmacology2026-01-12PMID 41521955
- Challenges Firefighters Face Getting Ketamine Therapy for PTSDkey findingJournal of Occupational and Environmental Medicine2026-01-16PMID 41540564
- Ketamine treatment may reduce suicidal thoughts in high-risk groupskey findingEpidemiology and psychiatric sciences2026-01-12PMID 41521819
- Psychedelic 5-HT2A activator increases natural and triggered 5-Hz brain waves in vision and memory-related areaskey findingCommunications biology2026-01-12PMID 41526476
Continue reading
All Psychedelic Science issuesGet the next Psychedelic Science issue
Seven papers, once a week. Free.